Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma Immunology Annual Scientific Meeting
JSPR Stock | USD 22.81 0.43 1.85% |
Slightly above 69% of Jasper Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Jasper Therapeutics suggests that many traders are alarmed. Jasper Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Jasper Therapeutics. Many technical investors use Jasper Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Jasper |
REDWOOD CITY, Calif., Oct. 24, 2024 -- Jasper Therapeutics, Inc. , a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria , chronic inducible urticaria and asthma, is presenting data from preclinical studies evaluating briquilimab at the American College of Allergy, Asthma Immunology Annua
Read at finance.yahoo.com
Jasper Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Jasper Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Jasper Therapeutics Fundamental Analysis
We analyze Jasper Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Jasper Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Jasper Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jasper Therapeutics stock to make a market-neutral strategy. Peer analysis of Jasper Therapeutics could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics with similar companies.
Peers
Jasper Therapeutics Related Equities
LYRA | Lyra Therapeutics | 10.53 | ||||
ELDN | Eledon Pharmaceuticals | 9.39 | ||||
XLO | Xilio Development | 7.92 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
IKNA | Ikena Oncology | 2.37 | ||||
HOOK | Hookipa Pharma | 1.61 | ||||
DSGN | Design Therapeutics | 0.50 | ||||
ABOS | Acumen Pharmaceuticals | 0.44 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
ORIC | Oric Pharmaceuticals | 0.70 | ||||
EPIX | ESSA Pharma | 1.10 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
INBX | Inhibrx | 2.37 | ||||
EQ | Equillium | 2.60 |
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.